コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 augmentation as an intervention in American cutaneous leishmaniasis.
2 tection against both Old World and New World cutaneous leishmaniasis.
3 oth a murine and a nonhuman primate model of cutaneous leishmaniasis.
4 ere investigated in an experimental model of cutaneous leishmaniasis.
5 for the synthesis of drugs effective against cutaneous leishmaniasis.
6 the treatment of parasitologically confirmed cutaneous leishmaniasis.
7 ration of PCR into diagnostic strategies for cutaneous leishmaniasis.
8 IgG antibodies in patients with visceral and cutaneous leishmaniasis.
9 n-activating gene(-/-) mice from progressive cutaneous leishmaniasis.
10 ol the parasite load and alter the course of cutaneous leishmaniasis.
11 uce protective immunity in a murine model of cutaneous leishmaniasis.
12 uman primate (rhesus monkey) models of human cutaneous leishmaniasis.
13 ssociated with increased pathology in murine cutaneous leishmaniasis.
14 mononuclear cells of patients with American cutaneous leishmaniasis.
15 and fully effective in this primate model of cutaneous leishmaniasis.
16 an absence of ulceration and necrosis during cutaneous leishmaniasis.
17 cells play a protective role in immunity to cutaneous leishmaniasis.
18 hmania major, one of the causative agents of cutaneous leishmaniasis.
19 anials and are more prone to develop chronic cutaneous leishmaniasis.
20 ses and, thereby, contributes to the cure of cutaneous leishmaniasis.
21 a, and south Asia had the highest DALYs from cutaneous leishmaniasis.
22 alence of sequalae of both acute and chronic cutaneous leishmaniasis.
23 apeutic target in both localized and diffuse cutaneous leishmaniasis.
24 between localized and drug-resistant diffuse cutaneous leishmaniasis.
25 arasites that cause unique clinical forms of cutaneous leishmaniasis.
26 esion size and parasite burden in a model of cutaneous leishmaniasis.
27 sepsis and ameliorated pathological signs of cutaneous leishmaniasis.
28 efosine has not been evaluated for pediatric cutaneous leishmaniasis.
29 Glucantime((R)) (meglumine antimoniate) for cutaneous leishmaniasis.
30 ned immunotherapeutic using a mouse model of cutaneous leishmaniasis.
31 intracellular protozoan parasite that causes cutaneous leishmaniasis.
32 hmaniasis, mucosal leishmaniasis and diffuse cutaneous leishmaniasis.
33 ells in determining the outcome of New World cutaneous leishmaniasis.
34 NF) can provide protection against New World cutaneous leishmaniasis.
35 understanding pathogenesis and protection in cutaneous leishmaniasis.
38 uviana endemicity were screened for American cutaneous leishmaniasis (ACL) infection by established P
39 robe, Gimblet et al. (2017) demonstrate that cutaneous leishmaniasis alters the human skin microbiota
40 investigated the role of skin microbiota in cutaneous leishmaniasis and found that human patients in
41 ania major, a protozoan parasite that causes cutaneous leishmaniasis and lacks TS and the TS product
42 ide a new perspective on the pathogenesis of cutaneous leishmaniasis and protozoan parasite-host inte
43 portant implications for the epidemiology of cutaneous leishmaniasis and suggest a vaccination strate
44 kin Mphi and DC are infected sequentially in cutaneous leishmaniasis and that they play distinct role
45 pacity to confer complete protection against cutaneous leishmaniasis and to prevent the establishment
46 ntibody titers were detected in sera of both cutaneous-leishmaniasis and visceral-leishmaniasis patie
48 T. cruzi (Chagas disease), Leishmania major (cutaneous leishmaniasis), and Plasmodium falciparum (mal
49 or Arg reduces infection severity in murine cutaneous leishmaniasis, and imatinib treatment results
50 ania chagasi in dermal scrapings of atypical cutaneous leishmaniasis, and L. mexicana from lesion asp
51 rican trypanosomiasis (HAT), Chagas disease, cutaneous leishmaniasis, and malaria) have an estimated
53 l global burden and assessed the equality of cutaneous leishmaniasis burden across different countrie
54 ward Th2 responses, which are detrimental in cutaneous leishmaniasis but beneficial in acute schistos
55 major and Leishmania braziliensis both cause cutaneous leishmaniasis, but the former kills BALB/c mic
61 umine antimoniate for treatment of pediatric cutaneous leishmaniasis caused by Leishmania (Viannia) s
62 ailure of pentavalent antimony treatment for cutaneous leishmaniasis caused by Leishmania braziliensi
63 mycin, with and without 0.5% gentamicin, for cutaneous leishmaniasis caused by Leishmania major in Tu
67 le in the susceptibility and pathogenesis of cutaneous leishmaniasis caused by the New World species,
71 saliva in 264 individuals, from an area for cutaneous leishmaniasis (CL) caused by Leishmania brazil
74 R methods for diagnosis of acute and chronic cutaneous leishmaniasis (CL) in an area of Colombia wher
75 uvant significantly reduced the incidence of cutaneous leishmaniasis (CL) in Ecuadorian children, com
77 ntrast, protective immunity against nonfatal cutaneous leishmaniasis (CL) is well defined and mediate
79 he clinical course of and immune response to cutaneous leishmaniasis (CL) treated with pentavalent an
80 08 household contacts (HCs) of patients with cutaneous leishmaniasis (CL) was established in 2010 in
81 biopsy specimens from patients with chronic cutaneous leishmaniasis (CL) were compared to those in b
82 of efficacy has been documented in Old World cutaneous leishmaniasis (CL), and different cure rates a
84 gumentary leishmaniasis (ATL) (also known as cutaneous leishmaniasis [CL]) is caused by various speci
85 tomatic or cause mild or severe skin ulcers (cutaneous leishmaniasis [CL]), limited or disseminated l
86 mononuclear cells (PBMCs) from patients with cutaneous leishmaniasis, CpG treatment similarly exhibit
89 Global and national data on the burden of cutaneous leishmaniasis disease are pivotal to promote f
90 mononuclear cells (PBMCs) from patients with cutaneous leishmaniasis due to Leishmania braziliensis a
93 DNA- and protein- based vaccines against cutaneous leishmaniasis due to Leishmania major were eva
96 nated mice was abrogated in vector-initiated cutaneous leishmaniasis, highlighting the importance of
97 the causative agents of trypanosomiasis, and cutaneous leishmaniasis, identifying several potent stru
98 results in effective treatment shortening of cutaneous leishmaniasis in a mouse model, while also enh
100 /kg/day for 5 days effects a radical cure of cutaneous leishmaniasis in Balb/c mice, as evidenced by
101 shmaniasis and, to a lesser extent, atypical cutaneous leishmaniasis in Central and South America.
102 amensis, the predominant etiologic agent for cutaneous leishmaniasis in Colombia, is characterized by
104 he parasite and its vector, the pathology of cutaneous leishmaniasis in humans and also the developme
105 Similar proportions of males and females had cutaneous leishmaniasis in most countries with a high in
106 ion with P8 PGLC provides protection against cutaneous leishmaniasis in susceptible BALB/c mice.
110 prints suggests that the present epidemic of cutaneous leishmaniasis in Timargara camp may be due to
111 is a promising vaccination strategy against cutaneous leishmaniasis inducing long-term protection ag
116 ania (Viannia) braziliensis causes localized cutaneous leishmaniasis (LCL) and mucocutaneous leishman
117 h DCL, compared with patients with localized cutaneous leishmaniasis (LCL) or with controls from an a
119 a (Viannia) braziliensis can cause localized cutaneous leishmaniasis (LCL), which heals spontaneously
122 clinical symptoms ranging from self-healing cutaneous leishmaniasis lesions to fatal visceral diseas
124 ed from mononuclear cells from patients with cutaneous leishmaniasis (Lm), once loaded with live meta
126 ectins, the immune pathology associated with cutaneous leishmaniasis might be ameliorated without com
127 tical for IL-12 production and resistance to cutaneous leishmaniasis, others suggest that this pathwa
129 veral of these Ags in PBMC from self-healing cutaneous leishmaniasis patients infected with either Le
133 or Leishmania major, which cause visceral or cutaneous leishmaniasis, respectively, elicited dramatic
134 untries had significantly greater DALYs from cutaneous leishmaniasis than the mean: Afghanistan (87.0
135 s is an important etiological agent of human cutaneous leishmaniasis that accounts for more than 8% o
137 nts with one to five ulcerative lesions from cutaneous leishmaniasis to receive a cream containing 15
139 , the global mean age-standardised DALYs for cutaneous leishmaniasis was 0.58 per 100 000 people.
140 infection, the inflammatory response during cutaneous leishmaniasis was evaluated in 129Sv/C57BL/6-r
141 e development of protective immunity against cutaneous leishmaniasis, we analyzed the course of cutan
143 2-12 years with parasitologically confirmed cutaneous leishmaniasis were randomized to directly obse
144 ishmaniasis are significantly lower than for cutaneous leishmaniasis; whether this is due to the high
145 e causative agent of Old World anthroponotic cutaneous leishmaniasis, which is characterized by lesio
146 d for a simple and efficacious treatment for cutaneous leishmaniasis with an acceptable side-effect p
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。